Dr Pallavi Tiwari's work is based on recent clinical findings that 90 per cent of the Glioblastoma Multiforme (GBM) recurrences occur close to the tumour margin, suggesting that malignant cells are present at the periphery of the tumour but are not visually discernible.
GBM is the most common and most aggressive cancer that begins within the brain.
Also Read
She said that despite several advances in drug discovery and clinical trials for cancer treatment, all GBM patients still follow the same 'one-fits-all' treatment regimen.
Tiwari, who is from Madhya Pradesh, presented her new research before at the Radiological Society of North America (RSNA) meeting recently.
"With Obama administration's push for personalised therapy, a pressing need in precision medicine is to identify patients with GBM who are suitable for specific clinical trials based on their tumour characterisation, instead of a 'one-size-fits-all' treatment," a media release said.
Unfortunately, this has not been feasible so far in the absence of reliable non-invasive and quantitative measurements regarding patient prognosis (likely outcome of the disease) in GBMs, Tiwari noted.
Tiwari and her team have shown on 62 patients that these computer-extracted features from tumour margins and its surrounding areas on MRI are together predictive of GBM outcomes, the press release said.
So far such an approach of investigating imaging features from normal-appearing areas outside of tumour margins has not been investigated.
Using computer techniques developed by Tiwari and her team, subtle information can be gleaned from normal-appearing regions (at tumour periphery) to allow for the ability to reliably and non-invasively stratify patients based on their survival and can ultimately guide personalised therapeutic clinical trials in GBM.
Tiwari graduated from SGSITS in Indore and moved to United States to get a PhD degree in Biomedical Engineering.
She is currently a research assistant professor in Biomedical Engineering and since 2012 has been working in early diagnosis, prognosis, and treatment evaluation of brain tumours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)